Tag: vaccine
1. One-fifth fractional doses from all four live attenuated yellow fever virus vaccines met the non-inferiority criterion.
2. The most common treatment-related adverse events were headache (22.2%), fatigue (13.7%), myalgia (13.3%), and self-reported fever (9.0%).
Evidence Rating Level: 1 (Excellent)
Study Rundown: Yellow fever is a mosquito-borne viral disease that is endemic...
Section 4: Johnson & Johnson One of Top 5 COVID-19 Vaccine Finalists
The Johnson & Johnson (J&J) Pharmaceutical Research and Development group has focused its COVID-19 vaccine efforts on a single-dose replication-defective human adenovirus 26 vector (Ad26.COV2.S).1,2,3 This vector deliver recombinant SARS-CoV-2 S protein genes to human cells. While no vaccines...
Section 3: Oxford/AstraZeneca Vaccine Shows Promise for Phase 3 Outcomes
With many COVID-19 vaccine being studied and approved for emergency use, one important candidate is the chimpanzee adenovirus-vector (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein.1 The University of Oxford developers of this vaccine have a partnership with AstraZeneca. This Phase 1/2...
1. The ChAdOx1 nCoV-19 vaccine against COVID-19 was well-tolerated overall, with reduced reactogenicity in older adults.
2. The ChAdOx1 nCoV-19 vaccine induced a robust SARS-CoV-2 spike-antibody response and showed similar immunogenicity across all age groups after a boost dose.
Evidence Rating Level: 1 (Excellent)
Study Rundown: As the SARS-CoV-2 virus continues to...
Section 5: Other Promising Vaccine Candidates and Considerations
Messenger RNA (mRNA) vaccines have offered a novel methodology in the context of COVID-19, including the Pfizer/BioNTech1 and Moderna2 vaccines. Rather than placing a weak or inactivated germ into the human body, mRNA vaccines utilize host cells to make a protein that...
Section 4: Johnson & Johnson One of Top 5 COVID-19 Vaccine Finalists
The Johnson & Johnson (J&J) Pharmaceutical Research and Development group has focused its COVID-19 vaccine efforts on a single-dose replication-defective human adenovirus 26 vector (Ad26.COV2.S).1,2,3 This vector deliver recombinant SARS-CoV-2 S protein genes to human cells. While no...
Section 3: Oxford/AstraZeneca Vaccine Shows Promise for Phase 3 Outcomes
With many COVID-19 vaccine being studied and approved for emergency use, one important candidate is the chimpanzee adenovirus-vector (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein.1 The University of Oxford developers of this vaccine have a partnership with AstraZeneca. This Phase...
Section 1: Pfizer/BioNTech Vaccine First to Receive Emergency Use Authorization to Prevent COVID-19
On December 11, 2020, the U.S. Food and Drug Administration (FDA) approved for emergency use the first vaccine to prevent coronavirus disease 2019 (COVID-19).1 This vaccine includes BNT162b2, a lipid nanoparticle-formulated, nucleoside-modified RNA and encodes a prefusion stabilized,...
Section 2: Moderna Vaccine Second to Receive Emergency Use Authorization
The FDA Advisory Committee met on December 17, 2020, ultimately recommending the Moderna vaccine’s approval for emergency use in the prevention of COVID-19. After hospitals across the U.S. began to receive batches of the Pfizer/BioNTech vaccine, Moderna has become the...
Section 1: Pfizer/BioNTech Vaccine First to Receive Emergency Use Authorization to Prevent COVID-19
On December 11, 2020, the U.S. Food and Drug Administration (FDA) approved for emergency use the first vaccine to prevent coronavirus disease 2019 (COVID-19).1 This vaccine includes BNT162b2, a lipid nanoparticle-formulated, nucleoside-modified RNA and encodes a prefusion...